$2.76 Billion is the total value of Camber Capital Management LP's 37 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
INNV | Exit | INNOVAGE HLDG CORP | $0 | – | -350,000 | -100.0% | -0.06% | – |
TBPH | Exit | THERAVANCE BIOPHARMA INC | $0 | – | -500,000 | -100.0% | -0.19% | – |
AVRO | Exit | AVROBIO INC | $0 | – | -1,633,333 | -100.0% | -0.22% | – |
ALKS | Exit | ALKERMES PLC | $0 | – | -1,300,000 | -100.0% | -1.04% | – |
IRWD | Exit | IRONWOOD PHARMACEUTICALS INC | $0 | – | -3,000,000 | -100.0% | -1.20% | – |
BIIB | Exit | BIOGEN INC | $0 | – | -250,000 | -100.0% | -2.06% | – |
SNY | Exit | SANOFIcall | $0 | – | -1,500,000 | -100.0% | -2.58% | – |
NVS | Exit | NOVARTIS AGcall | $0 | – | -1,000,000 | -100.0% | -3.01% | – |
VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -450,000 | -100.0% | -3.40% | – |
MRK | Exit | MERCK & CO INCcall | $0 | – | -2,000,000 | -100.0% | -5.27% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
MYLAN NV | 21 | Q3 2020 | 10.1% |
AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
Solid Biosciences Inc. | December 12, 2022 | ? | ? |
AVROBIO, Inc. | February 14, 2022 | ? | ? |
COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
Change Healthcare Inc. | February 16, 2021 | ? | ? |
GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
13F-HR | 2023-11-14 |
SC 13G | 2023-10-30 |
13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.